10 unknown. 10 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Unknown 10 |
| Phase 2 | 4 | Unknown 4 |
Follow Sars-CoV2: new trials by email Literature Review of Sars-CoV2 trials Research Report on Sars-CoV2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19 Peginterferon Lambda-1A, Placebo - Sars-CoV2, Covid19 | Phase 3 | Unknown | University Health Network, Toronto | 763 | 2021-08-27 | 2022-04-05 |
| Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19 Ribavirin Capsules, Favipiravir - SARS-CoV2, COVID-19 | Phase 2 / Phase 3 | Unknown | The Scientific and Technological Research Council of Turkey | 100 | 2021-04-01 | 2021-04-02 |
| Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) Hydroxychloroquine Only Product in Oral Dose Form - Sars-CoV2, Coronavirus Infection | Phase 2 / Phase 3 | Unknown | University of Malaga | 1930 | 2020-09-01 | 2020-09-29 |
| Clinical Trial to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers RUTI® vaccine, Placebo - Covid-19, Sars-CoV2 | Phase 3 | Unknown | Fundació Institut Germans Trias i Pujol | 315 | 2020-07-30 | 2020-07-29 |
| Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers BCG vaccine, Placebo - BCG, COVID-19 | Phase 3 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 908 | 2020-07-21 | 2020-11-13 |
| CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms Cannabidiol, PLACEBO - SARS-CoV2 | Phase 2 / Phase 3 | Unknown | University of Sao Paulo | 100 | 2020-07-06 | 2021-09-28 |
| Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19 SARS-CoV-2 convalescent plasma treatment, Standard care - Sars-CoV2, Covid-19 | Phase 2 / Phase 3 | Unknown | Fundación Santa Fe de Bogota | 236 | 2020-07-01 | 2020-06-11 |
| Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19 Favipiravir (3200 mg + 1200 mg), Favipiravir (3600 mg + 1600 mg), Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine - Sars-CoV2, COVID-19 | Phase 3 | Unknown | Ministry of Health, Turkey | 1008 | 2020-05-08 | 2021-02-01 |
| A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers Hydroxychloroquine, Hydroxychloroquine (placebo), Zinc - Sars-CoV2, COVID19 | Phase 3 | Unknown | Military Hospital of Tunis | 660 | 2020-05-04 | 2020-05-06 |
| Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP) Hydroxychloroquine, Placebo - COVID-19, Corona Virus Infection | Phase 3 | Unknown | Louisiana State University Health Sciences Center in New Orleans | 1700 | 2020-04-27 | 2020-09-02 |
COVID-19 (9) · Coronavirus Infections (3)
Coronaviridae Infections (9) · Infections (9) · Lung Diseases (9) · Nidovirales Infections (9) · Pneumonia (9) · Pneumonia, Viral (9) · RNA Virus Infections (9) · Respiratory Tract Diseases (9) · Respiratory Tract Infections (9) · Virus Diseases (9) · Coronavirus Infections (6)
Hydroxychloroquine (3) · favipiravir (2) · Azithromycin (1) · BCG Vaccine (1) · COVID-19 Serotherapy (1) · Cannabidiol (1) · Dosage Forms (1) · Ribavirin (1) · Standard of Care (1) · Zinc (1) · peginterferon lambda-1a (1)
Fundació Institut Germans Trias i Pujol (1) · Fundación Santa Fe de Bogota (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · Louisiana State University Health Sciences Center in New Orleans (1) · Military Hospital of Tunis (1) · Ministry of Health, Turkey (1) · The Scientific and Technological Research Council of Turkey (1) · University Health Network, Toronto (1) · University of Malaga (1) · University of Sao Paulo (1)
Turkey (Türkiye) (2) · Brazil (1) · Canada (1) · Colombia (1) · Mexico (1) · Spain (1) · Tunisia (1) · United States (1)
Faida Ajili, MD (1) · Jordan Feld, MD (1) · Juan C Morilla-Herrera, PhD (1) · Nejla Mrabet, PhD (1) · Pere-Joan Cardona, MD, PhD (1)